Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial

Konstantin Zhdanov,1 Vasily Isakov,2 Eduard Burnevich,3 Svetlana Kizhlo,4 Igor Bakulin,5 Vadim Pokrovsky,6 Liwen Liang,7 Peggy Hwang,7 Rohit Talwani,7 Barbara A Haber,7 Michael N Robertson7 1Military Medical Academy n.a. S.M. Kirov, St. Petersburg, Russia; 2Department of Gastroenterology & H...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhdanov K, Isakov V, Burnevich E, Kizhlo S, Bakulin I, Pokrovsky V, Liang L, Hwang P, Talwani R, Haber BA, Robertson MN
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	hepatitis c therapy placebo russia viral drug resistance Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/6c4a393d1b8042dd92afc7b5cc393396
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6c4a393d1b8042dd92afc7b5cc393396
record_format	dspace
spelling	oai:doaj.org-article:6c4a393d1b8042dd92afc7b5cc3933962021-12-02T05:14:15ZElbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial1179-1535https://doaj.org/article/6c4a393d1b8042dd92afc7b5cc3933962020-04-01T00:00:00Zhttps://www.dovepress.com/elbasvirgrazoprevir-for-hcv-infection-in-russia-a-randomized-trial-peer-reviewed-article-HMERhttps://doaj.org/toc/1179-1535Konstantin Zhdanov,1 Vasily Isakov,2 Eduard Burnevich,3 Svetlana Kizhlo,4 Igor Bakulin,5 Vadim Pokrovsky,6 Liwen Liang,7 Peggy Hwang,7 Rohit Talwani,7 Barbara A Haber,7 Michael N Robertson7 1Military Medical Academy n.a. S.M. Kirov, St. Petersburg, Russia; 2Department of Gastroenterology & Hepatology, Federal Research Centre of Nutrition, Biotechnology and Food Safety, Moscow, Russia; 3I.M. Sechenov First Moscow State Medical University, Moscow, Russia; 4City Center for AIDS and Infectious Diseases Treatment and Prophylaxis, St. Petersburg, Russia; 5I.I. Mechnikov North-Western State Medical University of the Ministry of Health of the Russian Federation, St. Petersburg, Russia; 6Department of AIDS, Central Research Institute of Epidemiology, Moscow, Russia; 7Merck & Co., Inc., Kenilworth, NJ, USACorrespondence: Barbara A HaberMerck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USATel +1 267-305-3729Email barbara.haber@merck.comPurpose: Hepatitis C virus (HCV) infection is a major healthcare concern in Russia, where almost 5 million individuals are viremic. Elbasvir/grazoprevir is a fixed-dose combination therapy for the treatment of HCV genotype 1 and genotype 4 infection. The present analysis aimed to assess the safety and efficacy of elbasvir/grazoprevir in individuals with HCV infection enrolled at Russian study sites in the C-CORAL study.Patients and Methods: C-CORAL (Protocol PN-5172-067; NCT02251990) was a Phase 3, placebo-controlled, double-blind study conducted throughout Asia and Russia. Treatment-naive participants with chronic HCV infection were randomly assigned to receive immediate or deferred treatment with elbasvir 50 mg/grazoprevir 100 mg once daily for 12 weeks. Participants in the immediate-treatment group received elbasvir/grazoprevir for 12 weeks, and those in the deferred-treatment group received placebo for 12 weeks, followed by open-label elbasvir/grazoprevir for 12 weeks. The primary endpoint was sustained virologic response at 12 weeks after completion of therapy (SVR12).Results: One hundred and nineteen Russian participants were randomized (immediate-treatment group, n=88; deferred-treatment group, n=31). Most participants were white (99%) with HCV genotype 1b infection (97%) and mild-to-moderate (F0–F2) fibrosis (70%). SVR12 was achieved by 98.9% participants in the immediate-treatment group and by 100% of those receiving deferred elbasvir/grazoprevir in the deferred-treatment group. One participant relapsed with nonstructural protein 5A (NS5A) L28M and Y93H resistance-associated substitutions at baseline and at time of failure. Drug-related adverse events were reported by 19% of participants receiving elbasvir/grazoprevir in the immediate-treatment group and by 16% of those receiving placebo in the deferred-treatment group. No serious adverse event or deaths occurred, and no participant discontinued treatment owing to an adverse event.Conclusion: Elbasvir/grazoprevir for 12 weeks was highly effective in treatment-naive Russian individuals with HCV genotype 1b infection.Keywords: hepatitis C, therapy, placebo, Russia, viral drug resistanceZhdanov KIsakov VBurnevich EKizhlo SBakulin IPokrovsky VLiang LHwang PTalwani RHaber BARobertson MNDove Medical Pressarticlehepatitis ctherapyplaceborussiaviral drug resistanceDiseases of the digestive system. GastroenterologyRC799-869ENHepatic Medicine: Evidence and Research, Vol Volume 12, Pp 61-68 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	hepatitis c therapy placebo russia viral drug resistance Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	hepatitis c therapy placebo russia viral drug resistance Diseases of the digestive system. Gastroenterology RC799-869 Zhdanov K Isakov V Burnevich E Kizhlo S Bakulin I Pokrovsky V Liang L Hwang P Talwani R Haber BA Robertson MN Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial
description	Konstantin Zhdanov,1 Vasily Isakov,2 Eduard Burnevich,3 Svetlana Kizhlo,4 Igor Bakulin,5 Vadim Pokrovsky,6 Liwen Liang,7 Peggy Hwang,7 Rohit Talwani,7 Barbara A Haber,7 Michael N Robertson7 1Military Medical Academy n.a. S.M. Kirov, St. Petersburg, Russia; 2Department of Gastroenterology & Hepatology, Federal Research Centre of Nutrition, Biotechnology and Food Safety, Moscow, Russia; 3I.M. Sechenov First Moscow State Medical University, Moscow, Russia; 4City Center for AIDS and Infectious Diseases Treatment and Prophylaxis, St. Petersburg, Russia; 5I.I. Mechnikov North-Western State Medical University of the Ministry of Health of the Russian Federation, St. Petersburg, Russia; 6Department of AIDS, Central Research Institute of Epidemiology, Moscow, Russia; 7Merck & Co., Inc., Kenilworth, NJ, USACorrespondence: Barbara A HaberMerck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USATel +1 267-305-3729Email barbara.haber@merck.comPurpose: Hepatitis C virus (HCV) infection is a major healthcare concern in Russia, where almost 5 million individuals are viremic. Elbasvir/grazoprevir is a fixed-dose combination therapy for the treatment of HCV genotype 1 and genotype 4 infection. The present analysis aimed to assess the safety and efficacy of elbasvir/grazoprevir in individuals with HCV infection enrolled at Russian study sites in the C-CORAL study.Patients and Methods: C-CORAL (Protocol PN-5172-067; NCT02251990) was a Phase 3, placebo-controlled, double-blind study conducted throughout Asia and Russia. Treatment-naive participants with chronic HCV infection were randomly assigned to receive immediate or deferred treatment with elbasvir 50 mg/grazoprevir 100 mg once daily for 12 weeks. Participants in the immediate-treatment group received elbasvir/grazoprevir for 12 weeks, and those in the deferred-treatment group received placebo for 12 weeks, followed by open-label elbasvir/grazoprevir for 12 weeks. The primary endpoint was sustained virologic response at 12 weeks after completion of therapy (SVR12).Results: One hundred and nineteen Russian participants were randomized (immediate-treatment group, n=88; deferred-treatment group, n=31). Most participants were white (99%) with HCV genotype 1b infection (97%) and mild-to-moderate (F0–F2) fibrosis (70%). SVR12 was achieved by 98.9% participants in the immediate-treatment group and by 100% of those receiving deferred elbasvir/grazoprevir in the deferred-treatment group. One participant relapsed with nonstructural protein 5A (NS5A) L28M and Y93H resistance-associated substitutions at baseline and at time of failure. Drug-related adverse events were reported by 19% of participants receiving elbasvir/grazoprevir in the immediate-treatment group and by 16% of those receiving placebo in the deferred-treatment group. No serious adverse event or deaths occurred, and no participant discontinued treatment owing to an adverse event.Conclusion: Elbasvir/grazoprevir for 12 weeks was highly effective in treatment-naive Russian individuals with HCV genotype 1b infection.Keywords: hepatitis C, therapy, placebo, Russia, viral drug resistance
format	article
author	Zhdanov K Isakov V Burnevich E Kizhlo S Bakulin I Pokrovsky V Liang L Hwang P Talwani R Haber BA Robertson MN
author_facet	Zhdanov K Isakov V Burnevich E Kizhlo S Bakulin I Pokrovsky V Liang L Hwang P Talwani R Haber BA Robertson MN
author_sort	Zhdanov K
title	Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial
title_short	Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial
title_full	Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial
title_fullStr	Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial
title_full_unstemmed	Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial
title_sort	elbasvir/grazoprevir for hcv infection in russia: a randomized trial
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/6c4a393d1b8042dd92afc7b5cc393396
work_keys_str_mv	AT zhdanovk elbasvirgrazoprevirforhcvinfectioninrussiaarandomizedtrial AT isakovv elbasvirgrazoprevirforhcvinfectioninrussiaarandomizedtrial AT burneviche elbasvirgrazoprevirforhcvinfectioninrussiaarandomizedtrial AT kizhlos elbasvirgrazoprevirforhcvinfectioninrussiaarandomizedtrial AT bakulini elbasvirgrazoprevirforhcvinfectioninrussiaarandomizedtrial AT pokrovskyv elbasvirgrazoprevirforhcvinfectioninrussiaarandomizedtrial AT liangl elbasvirgrazoprevirforhcvinfectioninrussiaarandomizedtrial AT hwangp elbasvirgrazoprevirforhcvinfectioninrussiaarandomizedtrial AT talwanir elbasvirgrazoprevirforhcvinfectioninrussiaarandomizedtrial AT haberba elbasvirgrazoprevirforhcvinfectioninrussiaarandomizedtrial AT robertsonmn elbasvirgrazoprevirforhcvinfectioninrussiaarandomizedtrial
_version_	1718400476132671488

Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial

Ejemplares similares